Article

Use of preclinical Alzheimer’s disease trajectories for clinical trial design

2025-05-02

Abstract excerpt

<h4>INTRODUCTION</h4> This study uses longitudinal amyloid biomarker and cognitive data to generate sample size estimates for two-armed, pre-clinical amyloid clearance clinical trials. <h4>METHODS</h4> PET PiB DVR ranges defined three amyloid groups (positive, “A+”; sub threshold/low positive, “subA+”; and negative, “A-”) in cognitively unimpaired Wisconsin Registry for Alzheimer’s Prevention participants. Amyloid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1aa1881a-1323-57cf-ac98-6219d63f61cc
DOI: 10.1101/2025.05.01.25326668

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Use of preclinical Alzheimer’s disease trajectories for clinical trial designDOI 10.1101/2025.05.01.25326668Read

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's diseaseSemantic proximity Read

Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general populationSemantic proximity Read

A data-driven Alzheimer’s disease progression simulator for retrospective validation and prospective Phase III power designSemantic proximity Read

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer’s Disease using PET and Plasma BiomarkersSemantic proximity Read

Tau-Connectome Subtypes and Solanezumab Response in Preclinical Alzheimer’s DiseaseSemantic proximity Read

Predicting future cognitive impairment in preclinical Alzheimer’s disease using multimodal imaging: a multisite machine learning studySemantic proximity Read

Clinical trials in predementia stages of Alzheimer disease.Semantic proximity Read

Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies (WeSHARE)Semantic proximity Read

Computational Risk Stratification of Preclinical Alzheimer’s in Younger AdultsSemantic proximity Read

Clinical and Pathological Progression of Awareness Trajectories in Preclinical Alzheimer’s DiseaseSemantic proximity Read

Scalable Markers for Early Cognitive Decline: Plasma p-tau217, Subjective Cognitive Concerns, and Digital Testing: Results from the A4/LEARN studiesSemantic proximity Read

Multi-method investigation of factors influencing amyloid onset and impairment in three cohortsSemantic proximity Read